Literature DB >> 8152364

Isolation of mycobacteria in patients with pulmonary alveolar proteinosis.

L A Witty1, V F Tapson, C A Piantadosi.   

Abstract

Pulmonary alveolar proteinosis (PAP) is a rare disorder characterized by accumulation of proteinaceous material in the alveoli of affected individuals. Pulmonary infections appear to develop with increased frequency in these patients. The increased rate of infection has been attributed to immunologic aberrations, such as impaired alveolar macrophage function, particularly when uncommon pathogens are involved. Among those pathogens, Nocardia asteroides and Mycobacterium tuberculosis have appeared most often in case reports in the literature. Mycobacterium avium-intracellulare (MAI) has rarely been isolated in these patients. We report an unusually high incidence of MAI isolation from lavage fluid in 8 of 19 consecutive patients who underwent therapeutic lung lavage for relief of symptomatic PAP, and summarize the available literature on isolation of potential respiratory pathogens in PAP.

Entities:  

Mesh:

Year:  1994        PMID: 8152364     DOI: 10.1097/00005792-199403000-00003

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.889


  24 in total

Review 1.  Management of nontuberculous mycobacterial infection in the elderly.

Authors:  Mehdi Mirsaeidi; Maham Farshidpour; Golnaz Ebrahimi; Stefano Aliberti; Joseph O Falkinham
Journal:  Eur J Intern Med       Date:  2014-03-29       Impact factor: 4.487

Review 2.  The molecular basis of pulmonary alveolar proteinosis.

Authors:  Brenna Carey; Bruce C Trapnell
Journal:  Clin Immunol       Date:  2010-03-25       Impact factor: 3.969

3.  Temporary remission of autoimmune pulmonary alveolar proteinosis after infectious episodes.

Authors:  Takehiko Kobayashi; Toru Arai; Masaki Hirose; Tomomi Homma; Akiko Matsumuro; Chikatoshi Sugimoto; Masanori Kitaichi; Masanori Akira; Yoshikazu Inoue
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2017-04-28       Impact factor: 0.670

Review 4.  Epidemiology of infection by nontuberculous mycobacteria.

Authors:  J O Falkinham
Journal:  Clin Microbiol Rev       Date:  1996-04       Impact factor: 26.132

Review 5.  Tuberculosis as a three-act play: A new paradigm for the pathogenesis of pulmonary tuberculosis.

Authors:  Robert L Hunter
Journal:  Tuberculosis (Edinb)       Date:  2016-01-02       Impact factor: 3.131

6.  Disseminated Cryptococcosis Due to Anti-Granulocyte-Macrophage Colony-Stimulating Factor Autoantibodies in the Absence of Pulmonary Alveolar Proteinosis.

Authors:  Chen-Yen Kuo; Shang-Yu Wang; Han-Po Shih; Kun-Hua Tu; Wen-Chi Huang; Jing-Ya Ding; Chia-Hao Lin; Chun-Fu Yeh; Mao-Wang Ho; Shi-Chuan Chang; Chi-Ying He; Hung-Kai Chen; Chen-Hsuan Ho; Chen-Hsiang Lee; Chih-Yu Chi; Cheng-Lung Ku
Journal:  J Clin Immunol       Date:  2016-12-24       Impact factor: 8.317

7.  Factors influencing numbers of Mycobacterium avium, Mycobacterium intracellulare, and other Mycobacteria in drinking water distribution systems.

Authors:  J O Falkinham; C D Norton; M W LeChevallier
Journal:  Appl Environ Microbiol       Date:  2001-03       Impact factor: 4.792

8.  Fluorescent acid-fast microscopy for measuring phagocytosis of Mycobacterium avium, Mycobacterium intracellulare, and Mycobacterium scrofulaceum by Tetrahymena pyriformis and their intracellular growth.

Authors:  E D Strahl; G E Gillaspy; J O Falkinham
Journal:  Appl Environ Microbiol       Date:  2001-10       Impact factor: 4.792

Review 9.  Immunodeficiency secondary to anticytokine autoantibodies.

Authors:  Sarah K Browne; Steven M Holland
Journal:  Curr Opin Allergy Clin Immunol       Date:  2010-12

10.  Anti-GM-CSF autoantibodies in patients with cryptococcal meningitis.

Authors:  Lindsey B Rosen; Alexandra F Freeman; Lauren M Yang; Kamonwan Jutivorakool; Kenneth N Olivier; Nasikarn Angkasekwinai; Yupin Suputtamongkol; John E Bennett; Vasilios Pyrgos; Peter R Williamson; Li Ding; Steven M Holland; Sarah K Browne
Journal:  J Immunol       Date:  2013-03-18       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.